Tag Archive for: mcrpc
Personalized Treatment for Advanced Prostate Cancer: The Power of Multi-Tracer PET Imaging
/0 Comments/in Preclinical Research/by MaxPhase 2 trial: Delaying Systemic Treatment in Metastatic Prostate Cancer – A New Approach
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPromising Results for 177Lu-PSMA-I&T in Prostate Cancer Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxBenfo-Oxythiamine Shows Promise as a Radiosensitizer in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPositive Phase 1 Data Supports Phase 2 of 177Lu rhPSMA-10.1 for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxDarolutamide Plus ADT: A Great Treatment Option for Metastatic Hormone-Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T castration-resistant prostate cancer clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC nanotechnology neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- New Method Uses Nanoparticles to Create CAR T Cells Inside Body for Cancer Treatment June 23, 2025
- Newsletter 25/2025 June 22, 2025
- Phase 1 Trial for ART-101, a Novel Radioligand Targeting PSMA in mCRPC June 21, 2025
- Phase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC June 20, 2025